Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Malalties hematològiques; Trastorns immunològics Enfermedades hematológicas; Trastornos inmunológicos Haematological diseases; Immunological disorders Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | Lozano, Maria L Mingot-Castellano, Maria E Perera, María M Jarque, Isidro Campos-Alvarez, Rosa M González-López, Tomás J Valcarcel Ferreiras, David |
description | Malalties hematològiques; Trastorns immunològics
Enfermedades hematológicas; Trastornos inmunológicos
Haematological diseases; Immunological disorders
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P |
format | Article |
fullrecord | <record><control><sourceid>csuc_XX2</sourceid><recordid>TN_cdi_csuc_recercat_oai_recercat_cat_11351_5868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_recercat_cat_11351_5868</sourcerecordid><originalsourceid>FETCH-csuc_recercat_oai_recercat_cat_11351_58683</originalsourceid><addsrcrecordid>eNqdjUsKAkEMRGfjQtQ75AAKDqK494MHcD-0sdoJOJ0mHQVv4nEdQXHvIhSh3kuG1XMLltzCJF0oG87CLndQDOxqhaIacavCII3krWl30qwCl0QGRu4xChdNUnxKbgjeITlFA3qgZE0FZUohnb-6CxPuPVSoPyJdd0v4dvxwzUgSxtUghmvB5JOjar7fHTeHGZcbN-_PxsEbDfJb3lPXi2XdLNer9eIP5QV3nmC5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia</title><source>Recercat</source><creator>Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M ; Jarque, Isidro ; Campos-Alvarez, Rosa M ; González-López, Tomás J ; Valcarcel Ferreiras, David</creator><creatorcontrib>Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M ; Jarque, Isidro ; Campos-Alvarez, Rosa M ; González-López, Tomás J ; Valcarcel Ferreiras, David</creatorcontrib><description>Malalties hematològiques; Trastorns immunològics
Enfermedades hematológicas; Trastornos inmunológicos
Haematological diseases; Immunological disorders
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P < 0.001), and to previous splenectomy in younger patients (100% vs. 33%, P = 0.001). Receiving romiplostim as first TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help clinicians make appropriate treatment decisions in the management of adult ITP patients with TPO-RA.</description><language>eng</language><publisher>Nature Publishing Group</publisher><subject>Blood Coagulation Disorders ; DISEASES ; drug therapy ; ENFERMEDADES ; enfermedades hematológicas ; enfermedades hematológicas y linfáticas ; farmacoterapia ; Hematologic Diseases ; Hemic and Lymphatic Diseases ; Medicaments - Administració ; Other subheadings ; Otros calificadores ; Purpura ; Purpura, Thrombocytopenic ; Purpura, Thrombocytopenic, Idiopathic ; púrpura ; púrpura trombocitopénica ; púrpura trombocitopénica idiopática ; trastornos de la coagulación sanguínea ; Trombocitopènia</subject><creationdate>2019-11</creationdate><rights>Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,778,883,26957</link.rule.ids><linktorsrc>$$Uhttps://recercat.cat/handle/11351/5868$$EView_record_in_Consorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$FView_record_in_$$GConsorci_de_Serveis_Universitaris_de_Catalunya_(CSUC)$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Lozano, Maria L</creatorcontrib><creatorcontrib>Mingot-Castellano, Maria E</creatorcontrib><creatorcontrib>Perera, María M</creatorcontrib><creatorcontrib>Jarque, Isidro</creatorcontrib><creatorcontrib>Campos-Alvarez, Rosa M</creatorcontrib><creatorcontrib>González-López, Tomás J</creatorcontrib><creatorcontrib>Valcarcel Ferreiras, David</creatorcontrib><title>Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia</title><description>Malalties hematològiques; Trastorns immunològics
Enfermedades hematológicas; Trastornos inmunológicos
Haematological diseases; Immunological disorders
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P < 0.001), and to previous splenectomy in younger patients (100% vs. 33%, P = 0.001). Receiving romiplostim as first TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help clinicians make appropriate treatment decisions in the management of adult ITP patients with TPO-RA.</description><subject>Blood Coagulation Disorders</subject><subject>DISEASES</subject><subject>drug therapy</subject><subject>ENFERMEDADES</subject><subject>enfermedades hematológicas</subject><subject>enfermedades hematológicas y linfáticas</subject><subject>farmacoterapia</subject><subject>Hematologic Diseases</subject><subject>Hemic and Lymphatic Diseases</subject><subject>Medicaments - Administració</subject><subject>Other subheadings</subject><subject>Otros calificadores</subject><subject>Purpura</subject><subject>Purpura, Thrombocytopenic</subject><subject>Purpura, Thrombocytopenic, Idiopathic</subject><subject>púrpura</subject><subject>púrpura trombocitopénica</subject><subject>púrpura trombocitopénica idiopática</subject><subject>trastornos de la coagulación sanguínea</subject><subject>Trombocitopènia</subject><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>XX2</sourceid><recordid>eNqdjUsKAkEMRGfjQtQ75AAKDqK494MHcD-0sdoJOJ0mHQVv4nEdQXHvIhSh3kuG1XMLltzCJF0oG87CLndQDOxqhaIacavCII3krWl30qwCl0QGRu4xChdNUnxKbgjeITlFA3qgZE0FZUohnb-6CxPuPVSoPyJdd0v4dvxwzUgSxtUghmvB5JOjar7fHTeHGZcbN-_PxsEbDfJb3lPXi2XdLNer9eIP5QV3nmC5</recordid><startdate>20191113</startdate><enddate>20191113</enddate><creator>Lozano, Maria L</creator><creator>Mingot-Castellano, Maria E</creator><creator>Perera, María M</creator><creator>Jarque, Isidro</creator><creator>Campos-Alvarez, Rosa M</creator><creator>González-López, Tomás J</creator><creator>Valcarcel Ferreiras, David</creator><general>Nature Publishing Group</general><scope>XX2</scope></search><sort><creationdate>20191113</creationdate><title>Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia</title><author>Lozano, Maria L ; Mingot-Castellano, Maria E ; Perera, María M ; Jarque, Isidro ; Campos-Alvarez, Rosa M ; González-López, Tomás J ; Valcarcel Ferreiras, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-csuc_recercat_oai_recercat_cat_11351_58683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Blood Coagulation Disorders</topic><topic>DISEASES</topic><topic>drug therapy</topic><topic>ENFERMEDADES</topic><topic>enfermedades hematológicas</topic><topic>enfermedades hematológicas y linfáticas</topic><topic>farmacoterapia</topic><topic>Hematologic Diseases</topic><topic>Hemic and Lymphatic Diseases</topic><topic>Medicaments - Administració</topic><topic>Other subheadings</topic><topic>Otros calificadores</topic><topic>Purpura</topic><topic>Purpura, Thrombocytopenic</topic><topic>Purpura, Thrombocytopenic, Idiopathic</topic><topic>púrpura</topic><topic>púrpura trombocitopénica</topic><topic>púrpura trombocitopénica idiopática</topic><topic>trastornos de la coagulación sanguínea</topic><topic>Trombocitopènia</topic><toplevel>online_resources</toplevel><creatorcontrib>Lozano, Maria L</creatorcontrib><creatorcontrib>Mingot-Castellano, Maria E</creatorcontrib><creatorcontrib>Perera, María M</creatorcontrib><creatorcontrib>Jarque, Isidro</creatorcontrib><creatorcontrib>Campos-Alvarez, Rosa M</creatorcontrib><creatorcontrib>González-López, Tomás J</creatorcontrib><creatorcontrib>Valcarcel Ferreiras, David</creatorcontrib><collection>Recercat</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Lozano, Maria L</au><au>Mingot-Castellano, Maria E</au><au>Perera, María M</au><au>Jarque, Isidro</au><au>Campos-Alvarez, Rosa M</au><au>González-López, Tomás J</au><au>Valcarcel Ferreiras, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia</atitle><date>2019-11-13</date><risdate>2019</risdate><abstract>Malalties hematològiques; Trastorns immunològics
Enfermedades hematológicas; Trastornos inmunológicos
Haematological diseases; Immunological disorders
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P < 0.001), and to previous splenectomy in younger patients (100% vs. 33%, P = 0.001). Receiving romiplostim as first TPO-RA with no subsequent TPO-RA switching was associated with a 50% likelihood of TFR after 2.9 years of therapy (3.3 years in chronic ITP patients). These real-world data help deciphering some areas of uncertainty, and offer insight into some of the most relevant challenges of ITP which may help clinicians make appropriate treatment decisions in the management of adult ITP patients with TPO-RA.</abstract><pub>Nature Publishing Group</pub><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_csuc_recercat_oai_recercat_cat_11351_5868 |
source | Recercat |
subjects | Blood Coagulation Disorders DISEASES drug therapy ENFERMEDADES enfermedades hematológicas enfermedades hematológicas y linfáticas farmacoterapia Hematologic Diseases Hemic and Lymphatic Diseases Medicaments - Administració Other subheadings Otros calificadores Purpura Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic púrpura púrpura trombocitopénica púrpura trombocitopénica idiopática trastornos de la coagulación sanguínea Trombocitopènia |
title | Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A38%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-csuc_XX2&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deciphering%20predictive%20factors%20for%20choice%20of%20thrombopoietin%20receptor%20agonist,%20treatment%20free%20responses,%20and%20thrombotic%20events%20in%20immune%20thrombocytopenia&rft.au=Lozano,%20Maria%20L&rft.date=2019-11-13&rft_id=info:doi/&rft_dat=%3Ccsuc_XX2%3Eoai_recercat_cat_11351_5868%3C/csuc_XX2%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |